Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Rating) – Equities research analysts at Cantor Fitzgerald lifted their FY2022 EPS estimates for Aligos Therapeutics in a research report issued to clients and investors on Thursday, November 3rd. Cantor Fitzgerald analyst P. Agrawal now expects that the company will earn ($2.23) per share for the year, up from […]
